Looking for Mankind Product ?
By Segment Name By product name
 
 
Home Company Profile Board Infrastructure R&D
Jobs Contact Us What's New

You & Your Health
Forgot Password
 
Enter Email:

Member's Login !
    User name
    Password
    Forget password? | Help

Mankind in focus
Mankind Pharma was launched in year 1995 with a goal to serve the suffering humanity. Mankind Pharma story has been quite similar to that of the pharma industry itself; there is nothing stopping either. In over a decade, the company has achieved more than what certain companies would achieve in a lifetime. In last one decade, the company has been ranked 7th in India and 4th in North India as per ORG-IMS. According to the Stockist Secondary Audit March 2006, the company ranked 13th position in India. Mankind\'s foresight, hard work and determination to perform better year after year has today made it a Rs 350 crore enterprise. In fact, the company has out-performed the growth of Indian Pharma Industry by growing at the rate of 60 percent year after year and ranking among the top 5 fastest growing Pharma companies in India. Hence, it came as no surprise when the company was named Emerging Company of the year at the Pharma Excellence Awards. \"When you start something only ten years back, coming here and standing here is like a dream come true. I am really proud to receive this award,\" expressed Rajeev Juneja, Marketing Director, Mankind Pharma while accepting the award. From a field force of 53 in 1995, today the total strength of the company has reached to 2600. Today, they have strong market presence in antibiotics, antifungal, gastrointestinal, NSAIDs, anthelmintics, cardiovascular, dermal and erectile dysfunction categories. In 2002 a new division, Discovery Mankind was launched. Today the division boasts of a field force of more than 700 field personnel and a turnover of almost 120 crore per annum. Encouraged by its success in May 2005, the company launched their new concern, Lifestar Pharma. According to the information posted on the website of the company, today the division boasts of a field force of more than 700 field personnel and turnover of almost 120 crore (2005-2006). On the number front, Mankind clocked in a total sales Rs 486.61 crore in 2006-07. This is a 43.17 percent rise over Rs 339.88 crore-the total sales for earlier year. The company does not have exports and is currently focussing on establishing themselves as a key player in the domestic pharma industry. The company\'s EBITDA (as a percentage of sales) has been between 11 and 12 percent for two years ie 2006-07 and 2005-06. It was 7.41 percent in 2004-05. From serving two states in 1995, today, mankind\'s products are available through out the length and breadth of the country including remote pockets served by 33 C&F agents. The company boasts of more than 2700 stocks countrywide. Mankind is also looking at entering the export market with launching some of its formulations within the South Asian market and semi regulated markets like South Africa and former CIS countries.
NEW DELHI: Mankind Pharma has tied up with diagnostics equipment major Roche Diagnostics India to market the new diabetes monitoring device Accu-Check Go. Pakistani cricketing legend Wasim Akram, who wants to promote diabetes awareness among the school children in the country, is Roche\'s brand ambassador for its another product Accu-Chek Active, currently available in the market for Rs 1,790. Accu-Check Go is an upgraded version of Accu-Chek Active and will be available in market for Rs 1,990. It comes with disposable capillary action test strips to prevent blood-related infections like HIV/AIDS, etc. Each test would cost a patient Rs 28.However, unlike the previous blood glucose monitoring equipment which is directly sold over the counter, Accu-Check Go will be promoted through doctors by Mankind in 500 towns across India. Mankind hopes to add about Rs200 crore to its revenues in the next five years with this new deal. \"In the first year itself, the new business would contribute Rs20 crore to our revenues while in the next five years we expect a turnover of Rs200 crore through this agreement,\"said R C Juneja, managing director of Mankind Pharma. \"The focus of this venture is to communicate the importance of diabetes management and at the same time increase the availability of efficient tools for people with diabetes and their caregivers,\" said Juneja. Mankind will also hold road shows and about 2000 camps to create awareness, especially in the rural areas and schools. Mankind is also planning to step out into newer markets, including the US, to become a Rs 1,000 crore company over the next three years. The company has plans to set up marketing offices in Nepal and Burma. Currently, the company operates in the domestic drug market with 44 brands. \"We would soon tap South Asian market and Russia which offer a huge growth potential. The company has already applied for registering 20 products in these countries,\"Juneja said.
NEW DELHI: The domestic pharma market recorded nearly 10% growth in July - the highest after a gap of three months, riding on higher sales of therapies such as cardiovascular and anti-diabetics (chronic segment). The growth rate in May was 7.5%, while in June it had dipped to 6.2%. Amongst the top performers during the month were Ranbaxy with over 13% growth, Sun Pharma 14%, Piramal Healthcare 11.6% and Mankind Pharma 27%. The growth rate in chronic segments like cardiovascular, anti-diabetics and ophthalmology or specialty products, such as hormones, showed a robust growth, over 20% in most cases, the latest figures from ORG-IMS showed. Overall the market in July was valued at Rs 3,164 crore. On a moving annual total basis (August 07-July08), the overall market grew 13.2% with the chronic segment growing at 19%, with the acute segment trailing behind at 12%. The anti-infective segment had shown a huge spurt during January-May period, which was attributed to early onset of rains, and rise in viral and other infections. Analysts pointed out that with the rise in lifestyle diseases, cardio-vascular and anti-diabetic segments are now the fastest growing therapeutic areas. Says Pfizer India director, medical and regulatory affairs, Dr Chandrashekhar Potkar: \"WHO projects that over the next 10 years in India, over 60 million people will die from a chronic disease. Death due to cardiovascular diseases is also expected to double by the year 2020. Hypertension is directly responsible for 57% of all stroke deaths and 24% of all coronary heart disease deaths in India.\"

Media Centre

Social Commitment

B2B

Financials
Company Profile | Chairman’s statement | Infrastructure | Feedback | Contact Us | Privacy Policy | FAQ | PDF downloads | Sitemap | Terms of Use
Conceptualized, Designed & Developed by :ACG Infotech Limited Copyright © 2008 Mankind pharma.All Right Reserved